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Abstract 
Background: There is concern that cannabis use negatively affects vulnerable groups such as youth; however, the 
relationship between cannabis use and health care utilization has not been well characterized in this population. We 
longitudinally evaluated the association between daily cannabis use and hospitalization among a prospective cohort 
of street‑involved youth.
Methods: Data were collected from the At‑Risk Youth Study (ARYS) in Vancouver, Canada, from September 2005 to 
May 2015. Participants were interviewed semi‑annually and multivariable generalized estimating equation (GEE) logis‑
tic regression was used to examine the relationship between daily cannabis use and hospitalization.
Results: A total of 1216 participants (31.2% female) were included in this analysis, and 373 (30.7%) individuals 
reported hospitalization at some point during the study period. In a multivariable GEE analysis, daily cannabis use 
was not significantly associated with hospitalization (Adjusted Odds Ratio [AOR] = 1.17, 95% Confidence interval 
[CI] = 0.84, 1.65). We did observe a significant interaction between daily cannabis use and sex (AOR = 0.51, 95% 
CI = 0.34, 0.77), whereby cannabis use was associated with a decreased odds of hospitalization among males 
(AOR = 0.60, 95% CI = 0.47, 0.78), yet was not significantly associated with hospitalization among females (AOR = 1.19, 
95% CI = 0.84, 1.67).
Conclusions: The finding that daily cannabis use was not associated with hospitalization among street‑involved 
youth is encouraging given the high rates of cannabis use in this population and the expansion of cannabis legali‑
zation and regulation. Future studies, however, are warranted to monitor possible changes in the consequences of 
cannabis use as cannabis legalization and regulation increase internationally.
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Background
Cannabis remains the world’s most widely produced, traf-
ficked and consumed illicit drug and concerns have been 
raised about the potential harms associated with acute 
and chronic cannabis use, including problems with cog-
nitive and psychomotor functioning, respiratory diseases, 
dependence and mental illness [1–4]. Some emerging 
evidence suggests that adolescents and young adults 
may be uniquely vulnerable to the long-term effects of 
intense or chronic cannabis use due to the neurological, 
social and educational development that occurs during 
this period [5, 6]. As a result, young adults experiencing 
acute (e.g., accident-related injuries) or long-term (e.g., 
dependence, educational attainment) harm from can-
nabis use may account for a greater overall burden of ill-
ness compared to older individuals who experience these 
outcomes [7–10]. A 2017 analysis showed that among 
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repeated users, the average age of first cannabis use was 
18.6 years and more than 50% of cannabis users reported 
repeated use before the age of 18 [11].
Although several studies have reported on harms 
associated with cannabis use, work in this area remains 
controversial and the extent of these harms has been 
difficult to quantify [12]. High-intensity cannabis use 
has been linked to a risk of respiratory complications, 
yet experts have questioned the strength of this asso-
ciation and nearly half of past-year cannabis users also 
smoke tobacco making it likely that tobacco is either a 
substantial contributor or primary cause of the associa-
tion between cannabis use and respiratory diseases [13, 
14]. The cognitive and psychomotor impairments of can-
nabis have also been described although these changes 
typically dissipate in adults after use has been discontin-
ued for several weeks, and some work suggests that the 
observed effects might be explained by socioeconomic 
differences [8, 12]. Even among young people who may 
be more susceptible to the adverse effects of cannabis 
use, severe harms only occur in a minority of users and 
the vast majority does not experience mental illness or 
dependence [6, 15–17].
Nevertheless, the morbidity and mortality associated 
with cannabis use remains a public health concern, par-
ticularly in countries implementing cannabis legalization 
policies. Studies from the USA and Europe have reported 
elevated rates of hospitalization among people who use 
cannabis and significant increases in cannabis-related 
hospitalizations were observed throughout the intro-
duction of cannabis legalization in Colorado [18–20]. In 
Canada, cannabis-attributable lung cancer represents the 
largest contributor to mortality among people who use 
cannabis, while cannabis use disorder was the primary 
contributor to the overall cannabis burden of disease 
[16]. The burden of disease associated with cannabis also 
varied by age and sex, with the highest burden occurring 
among young people and males accounted for twice as 
much burden as females [16]. Prior studies have demon-
strated that men and women differ in the prevalence of 
cannabis use and cannabis use disorder, drug tolerance, 
health outcomes and treatment-seeking behavior related 
to cannabis use [21–23]. Compared to women, men typi-
cally; initiate cannabis use at a younger age; have greater 
access to cannabis; are more likely to use frequently and 
in higher quantities; are more likely to be long-term 
users; and are twice as likely to be diagnosed with a can-
nabis use disorder [24, 25]. However, women have been 
found to have more severe symptoms associated with 
cannabis withdrawal such as nausea and anxiety [26, 27]. 
Among patients hospitalized for injury-related events, 
men who used cannabis exhibited increased rates of 
injuries resulting from motor vehicle accidents, assault 
and self-inflicted injuries compared to non-users [18]. 
Women who used cannabis were only more likely to sus-
tain self-inflicted injuries compared to non-users [18]. 
Many large-scale studies have also found that women are 
significantly more likely than men to access healthcare 
services including primary and specialty care [28, 29].
A recent study of emergency department access 
reported significant increases in emergency department 
visits related to cannabis use, with the largest increase 
observed among youth [30]. Youth who use drugs and 
are street-involved (homeless or use homeless youth 
services) are at an increased risk to initiate high-risk 
substance use such as injection drug use and engage in 
high-risk behaviors including binging and needle shar-
ing [31–33]. As a result, they experience increased rates 
of infectious diseases, mental illness, intentional and 
unintentional injuries and overdoses [34, 35]. For many 
of these patients, hospitalization is necessary due to the 
complications associated with these comorbidities [36]. 
However, barriers such as transportation, cost, fear of 
judgment and lack of trust often discourage these youth 
from accessing health and social services to address these 
health vulnerabilities [37, 38]. Avoiding services for these 
health issues often allows them to deteriorate until they 
require hospitalization, which increases the health and 
economic burden associated with treating these condi-
tions [35, 37, 39, 40]. Previous studies of street-involved 
youth have found that nearly one-third report being hos-
pitalized in the last 6  months and many authors have 
raised concerns about how cannabis use affects the acute 
and long-term health of vulnerable populations such as 
economically disadvantaged youth [41, 42].
The risk environment for young people who use drugs, 
including the social, environmental and structural fac-
tors that mediate health outcomes, is changing with the 
expansion of legal and regulated cannabis throughout 
North America [43]. Rhodes’ Risk Environment Frame-
work outlines how social, structural and environmental 
factors shape health-related behaviors and health care 
service utilization [44]. Among people who use drugs, 
this framework can be applied to examine the interac-
tions between social and structural factors with individ-
ual factors and how these interactions influence high-risk 
practices and health service access among vulnerable 
populations [45]. Given that few studies have examined 
the impact of cannabis use on health care utilization and 
associated expenditures such as hospitalization, particu-
larly among youth, we sought to longitudinally evaluate 
if high-intensity cannabis use was associated with hospi-
talization among a prospective cohort of street-involved 
youth who use illicit drugs. To account for the sex differ-
ences in the prevalence of cannabis use and health out-
comes associated with cannabis  use, we also examined 
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sex × cannabis use interaction effects to determine if the 
effect of high-intensity cannabis use on hospitalization 
was different among males and females.
Methods
The data for this analysis were collected from the At-
Risk Youth Study (ARYS). ARYS is an open ongoing pro-
spective cohort of street-involved youth that has been 
described in detail previously [46]. Briefly, participants 
were recruited through snowball sampling and extensive 
street outreach methods in Vancouver, Canada. Eligibility 
criteria included: being aged 14–26 years at the time of 
recruitment; illicit drug use other than or in addition to 
cannabis in the past 30 days; providing written informed 
consent; and street-involved, defined as being without 
stable housing or accessing street-based youth services 
in the past 6  months [47]. An interviewer-administered 
questionnaire was completed by participants at baseline 
and every 6-months thereafter to collect data related to 
socio-demographic information, substance use behaviors 
and engagement with health and social services. Partici-
pants were remunerated $30 CAD as compensation for 
each interview, and the ARYS study has been approved 
by the University of British Columbia’s Research Ethics 
Board.
This study included all ARYS participants recruited 
between September 2005 and May 2015. The main out-
come was any experience of hospitalization in the past 
6  months. This was assessed through self-report based 
on the item, “Have you been admitted to the hospital in 
the last 6 months (yes vs. no). Participants who answered 
affirmatively then specified the specific condition that 
they were admitted for based on the item, “In the last 
6  months, what serious medical condition or condi-
tions were you hospitalized for (endocarditis, cellulitis, 
abscess, pneumonia, surgery, osteomyelitis, liver failure, 
mental health issues, infection, drug-related (e.g., over-
dose, withdrawal), other)?” The primary explanatory vari-
able of interest was daily cannabis use (≥ daily vs. < daily). 
Cannabis use was measured based on the item, “In the 
last 6 months, how often have you used marijuana?” The 
response options include, "0 = less than once a month, 
1 = 1–3 times a month, 2 = Once a week, 3 = 2 or more 
times a week, 4 = at least daily.” These categories were 
collapsed to ≥ daily vs. < daily due to the low prevalence 
of occasional users (e.g., “less than once a month” and 
“1–3 times per month”) and analyzing these as individual 
categories can produce unstable estimates of effect size.
Additional factors potentially associated with hospi-
talization were also included in the analysis. These vari-
ables included: age (per year older); sex (male vs. female); 
ethnicity/ancestry (White vs. others); homelessness (yes 
vs. no); mental illness (yes vs. no), recent injection drug 
use (yes vs. no); heavy alcohol use (yes vs. no); frequent 
heroin use (≥ daily vs. < daily); frequent cocaine use 
(≥ daily vs. < daily); frequent crack use (≥ daily vs. < daily); 
frequent methamphetamine use (≥ daily vs. < daily); non-
fatal overdose (yes vs. no); and any alcohol or drug treat-
ment (yes vs. no). The measurement of mental illness was 
based on self-report, and defined as any diagnosis of a 
mental health disorder at baseline or over follow-up. At 
baseline, this was assessed based on the item “Have you 
ever been diagnosed with a mental health issue (yes vs. 
no)?” Over follow-up, this was assessed based on the 
item, “Have you been diagnosed with a mental health 
issue in the last 6 months? (yes vs. no).” Participants who 
self-reported one or more diagnosis including depression, 
obsessive–compulsive disorder, schizophrenia, post-trau-
matic stress disorder (PTSD), drug-induced psychosis, 
bipolar disorder, attention-deficit disorder, attention-def-
icit hyperactivity disorder, oppositional defiance disor-
der, personality disorders, sleep disorders or other were 
classified and having a mental illness. Heavy alcohol use 
was defined based on the National Institute on Alcohol 
Abuse and Alcoholism (NIAAA) definition of risky alco-
hol use: > 14 drinks/ week or > 4 drinks on 1 occasion for 
men < 65  years of age, and > 7 drinks/week or > 3 drinks 
on 1 occasion for all women and men ≥ 65  years of age 
[48]. Each of the covariates, as well as the outcome and 
primary explanatory variable of interest were time-vary-
ing and assessed at baseline and semi-annually through 
the interviewer-administered questionnaire. All behav-
ioral variables referred to the preceding 6-month period 
and the variable definitions were based on previous stud-
ies [49].
Baseline characteristics of the study sample, stratified 
by cannabis use in the last 6 months, were analyzed using 
Cochran–Armitage trend test for categorical variables 
and Kruskal–Wallis test for continuous variables. Gener-
alized estimating equation (GEE) logistic regression was 
used for the analysis of correlated follow-up data to iden-
tify factors associated with being hospitalized in the past 
6-months. GEE were used since this method provides 
standard errors adjusted for multiple observations for 
each participant over follow-up using an exchangeable 
correlation structure and can be applied to participants 
with varying numbers of observations [50–54]. Before 
conducting the primary analysis, bivariable GEE analyses 
were performed to determine the associations between 
hospitalization and each of the variables of interest. The 
multivariable model was fit using an a priori-defined 
statistical protocol based on the quasi-likelihood under 
the independence model criterion (QIC) for GEE and p 
values [55]. The initial multivariable model included all 
explanatory variables associated with hospitalization in 
the bivariable analyses at the level of p < 0.10. Reduced 
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models were built by sequentially removing each variable 
with the highest p value, and the final model included 
the set of variables associated with the lowest quasi-like-
lihood under the independence model criterion (QIC). 
Given the sex differences in the prevalence of cannabis 
use, we also included a sex × cannabis interaction term 
to determine if the effect of cannabis use on hospitaliza-
tion was different among males and females [56]. All sta-
tistical analyses were conducted using R version 3.2.4 (R 
Core Team, Vienna, Austria). All p values are two sided.
Results
Between September 2005 and May 2015, a total of 1216 
participants completed at least one follow-up visit and 
were included in the present study: 379 (31.2%) were 
female and the median age at baseline was 21.8  years 
(interquartile range [IQR] 19.8–23.6 years). The median 
number of study visits completed by the participants 
was three (IQR = 1–5) and the median observation time 
per participant was 17.1  months (IQR = 0–32.6). At 
baseline, 530 (43.6%) participants reported at least daily 
cannabis use in the last 6 months and 151 (12.4%) indi-
viduals reported experiencing a hospitalization in the 
last 6  months. The baseline characteristics of the study 
sample stratified by cannabis use in the last 6 months are 
shown in Table 1.
As indicated in Table 2, the bivariable analyses revealed 
that factors positively associated with hospitaliza-
tion included: homelessness (odds ratio [OR] = 1.41; 
95% confidence interval [CI]: 1.18, 1.68); mental ill-
ness (OR = 1.87; 95% CI 1.50, 2.35); daily cocaine use 
(OR = 2.35; 95% CI 1.50, 3.70); non-fatal overdose 
(OR = 1.98; 95% CI 1.55, 2.51); and participation in alco-
hol or drug treatment (OR = 1.58; 95% CI 1.33, 1.89). 
Daily cannabis use was the only factor negatively asso-
ciated with hospitalization in the bivariable analysis 
(OR = 0.70; 95% CI 0.58, 0.85).
The results of the multivariable analysis of factors asso-
ciated with hospitalization are also presented in Table 2. 
Factors that remained positively associated with hos-
pitalization included: homelessness (AOR = 1.44; 95% 
CI 1.18, 1.76); mental illness (AOR = 1.74; 95% CI 1.38, 
2.20); daily cocaine use (AOR = 2.02; 95% CI 1.28, 3.20); 
non-fatal overdose (AOR = 1.73; 95% CI 1.34, 2.22); and 
participation in alcohol or drug treatment (AOR = 1.45; 
95% CI 1.21, 1.74). Daily cannabis use was not signifi-
cantly associated with hospitalization in the multivari-
able model (AOR = 1.17; 95% CI 0.84, 1.65). We observed 
a significant interaction between daily cannabis use 
and sex (AOR = 0.51; 95% CI 0.34, 0.77), whereby daily 
cannabis use was not associated with hospitalization 
among females (AOR = 1.19; 95% CI 0.84, 1.67) but 
was negatively associated with hospitalization among 
Table 1 Baseline characteristics among street‑involved youth 
who use illicit drugs in Vancouver, Canada (n = 1216)
Bold values indicate p values < 0.05
a Refers to activities in the 6 months prior to follow-up interview, not all cells add 
up to 1216 as participants may choose not to answer certain questions
Daily cannabis use in the past 6 months
No (n = 682)
n (%)
Yes (n = 530)
n (%)
p value
Age (per additional year)
Median (IQR) 21.9 (19.9–23.7) 21.8 (19.7–23.6) 0.502
White ethnicity
Yes 454 (66.6) 362 (68.3) 0.539
No 226 (33.1) 167 (31.5)
Sex
Male 412 (60.4) 421 (79.4) < 0.001
Female 270 (39.6) 109 (20.6)
Homelessa
Yes 503 (73.8) 397 (74.9) 0.777
No 175 (25.7) 133 (25.1)
Mental illness
Yes 352 (51.6) 278 (52.5) 0.772
No 330 (48.4) 252 (47.5)
Injection drug usea
Yes 265 (38.9) 137 (25.8) < 0.001
No 416 (61.0) 392 (74.0)
Heavy alcohol use
Yes 234 (34.3) 198 (37.4) 0.286
No 445 (65.2) 331 (62.5)
Hospitalizationa
Yes 101 (14.8) 50 (9.4) 0.005
No 581 (85.2) 480 (90.6)
Frequent heroin usea
≥ Daily 99 (14.5) 37 (7.0) < 0.001
< Daily 576 (84.5) 486 (91.7)
Frequent cocaine usea
≥ Daily 20 (2.9) 17 (3.2) 0.790
< Daily 656 (96.2) 510 (96.2)
Frequent crack usea
≥ Daily 103 (15.1) 80 (15.1) 0.965
< Daily 577 (84.6) 445 (84.0)
Frequent methamphetamine usea
≥ Daily 92 (13.5) 70 (13.2) 0.889
< Daily 584 (85.6) 455 (85.8)
Non-fatal overdosea
Yes 95 (13.9) 75 (14.2) 0.908
No 585 (85.8) 453 (85.5)
Drug or alcohol treatmenta
Yes 227 (33.3) 146 (27.5) 0.031
No 448 (65.7) 379 (71.5)
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males (AOR = 0.60; 95% CI 0.47, 0.78). This indicates 
that the odds of hospitalization are decreased by 40% 
(1–0.6 = 0.4) among males compared to females, and that 
the probability of hospitalization associated with being 
male is 37.5% (p = OR / (1 + OR)).
Discussion
In this prospective cohort study, we observed a high 
prevalence of daily cannabis use among a community-
recruited sample of street-involved youth in Vancouver, 
Canada. In our multivariable analysis, daily cannabis 
use was not significantly associated with recent hospi-
talization. Although, we observed a significant inter-
action between sex and cannabis use whereby daily 
cannabis use was not significantly associated with hos-
pitalization among females, yet was negatively associ-
ated with hospitalization among males. Consistent with 
the Risk Environment Framework, both individual and 
structural factors were associated with hospitaliza-
tion, including homelessness, frequent cocaine use, 
experiencing a non-fatal overdose and participation 
in alcohol or drug treatment. These associations were 
Table 2 Bivariable and multivariable GEE analysis of factors associated with hospitalization (n = 1216)
Bold values indicate p values < 0.05
a Refers to activities in the 6 months prior to follow-up interview
Characteristic Unadjusted Adjusted Subgroup analysis
Odds ratio
(95% CI)
p value Odds ratio
(95% CI)




(≥ Daily vs. < daily) 0.70 (0.58–0.85) < 0.001 1.17 (0.84–1.65) 0.359
Frequent cannabis  usea × Sex 
interaction
– – 0.51 (0.34–0.77) 0.002
Frequent cannabis use among females 1.19 (0.84–1.67) 0.327
Frequent cannabis use among males 0.60 (0.47–0.78) < 0.001
Age
(Per additional year older) 1.00 (0.97–1.03) 0.773
White ethnicity
(Yes vs. no) 1.05 (0.82–1.34) 0.703
Sex
(Female vs. male) 0.90 (0.72–1.13) 0.363 1.17 (0.89–1.55) 0.255
Homelessa
(yes vs. no) 1.41 (1.18–1.68) < 0.001 1.44 (1.18–1.76) < 0.001
Mental illness
(Yes vs. no) 1.87 (1.50–2.35) < 0.001 1.74 (1.38–2.20) < 0.001
Injection drug usea
(yes vs. no) 1.29 (1.05–1.57) 0.013
Heavy alcohol use
(Yes vs. no) 0.97 (0.78–1.20) 0.766
Frequent heroin usea
(≥ Daily vs. < daily) 1.11 (0.87–1.41) 0.396
Frequent cocaine usea
(≥ daily vs. < daily) 2.35 (1.50–3.70) < 0.001 2.02 (1.28–3.20) 0.003
Frequent crack usea
(≥ Daily vs. < daily) 1.13 (0.85–1.50) 0.417
Frequent methamphetamine usea
(≥ Daily vs. < daily) 1.13 (0.88–1.45) 0.340
Non-fatal overdosea
(Yes vs. no) 1.98 (1.55–2.51) < 0.001 1.73 (1.34–2.22) < 0.001
Drug or alcohol treatmenta
(yes vs. no) 1.58 (1.33–1.89) < 0.001 1.45 (1.21–1.74) < 0.001
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observed after adjustment for a range of possible socio-
demographic and drug use confounders.
There is evidence to explain the lack of association 
between cannabis use and hospitalization. Specifically, 
people who use cannabis may reflect a subgroup of peo-
ple who use drugs that are averse to the risks associated 
with other illicit drug use and injection drug use, such as 
the perceived risks of addiction, dependence and inter-
ference with life goals [57, 58]. However, this explanation 
may not apply since we adjusted for the use of a number 
of high-risk drugs in the multivariable analysis. There is 
also emerging evidence to suggest that cannabis may be 
used by some individuals to intentionally reduce the use 
of “high-risk substances” including crack-cocaine and 
opioids [59, 60]. Cannabis has been used intentionally 
and effectively to reduce cocaine-related craving symp-
toms and the use of crack-cocaine among people who 
use illicit drugs [61]. Frequent cannabis use has also been 
associated with decreased illicit opioid use and exposure 
to fentanyl among people who use drugs [62, 63]. Pre-
vious studies have also found that cannabis was often 
intentionally used as a method to “self-detox,” decrease 
the severity of their addiction, transition to less danger-
ous routes of substance administration and to maintain 
low-intensity heroin use or transition off of heroin [64, 
65]. Cannabinoid receptors operate in part through an 
opioid receptor mechanism and increase the concentra-
tions of dopamine in the nucleus accumbens, similar to 
heroin and other commonly used opioids [66–68]. Exist-
ing studies have demonstrated independent analgesic 
effects of cannabis and improved analgesia when opioids 
are supplemented with a cannabinoid CB1 agonist [69, 
70]. Since the use of crack-cocaine and licit and illicit opi-
oids has been linked to health and social harms including 
increased risk of HIV, hepatitis C virus, comorbid mental 
illness, and overdose, decreased hospitalization among 
people who use cannabis may be an indirect effect of 
cannabis users reducing the use of high-risk substances 
[71–73].
Another explanation for the lack of association between 
cannabis use and hospitalization may involve the type of 
harm caused by cannabis. Cannabis attributed lung can-
cer, cannabis use disorder and motor vehicle accidents 
are the primary sources of disease burden associated 
with cannabis use [16]. Since cannabis associated lung 
cancer and cannabis use disorder are more likely to affect 
older individuals with a long history of chronic cannabis 
use, it is possible that these harms were not yet detect-
able in our cohort. In addition, some authors have chal-
lenged the link between cannabis use and lung cancer, 
and a previous systematic review failed to identify a sig-
nificant association between cannabis use and lung can-
cer after adjustment for tobacco use [14]. Many of these 
participants are also experiencing financial hardship and 
do not have access to motor vehicles, which may have 
reduced the prevalence of driving under the influence of 
cannabis. Acute paranoia and psychosis associated with 
poly-substance use is another potential source of hospi-
talization, yet the relative safety of cannabis and the other 
risks of hospitalization among this cohort may explain 
the non-significant association we observed [16, 74].
The cannabis use × sex interaction we observed 
indicated that daily cannabis use was associated with 
decreased hospitalization among males, yet was not sig-
nificantly associated with hospitalization among females. 
It is possible that youth who use drugs, particularly 
males, avoid accessing health services due to the fear of 
stigma associated with their substance use [75]. Men are 
significantly less likely than women to seek help for both 
medical and psychological health issues, and the stigma 
associated with illicit drug use may compound the avoid-
ance of health care services among young male cannabis 
users [75, 76].
As suggested by the Risk Environment Framework, 
both individual and structural factors were significantly 
associated with hospitalization. Consistent with previous 
studies, substance use related factors including frequent 
cocaine use and non-fatal overdose were associated 
with an increased risk of hospitalization in this sample 
[41]. Due to the short half-life of cocaine (40–60  min), 
cocaine users often use over 20 times per day and are an 
increased risk of cardiovascular complications, psychotic 
episodes and acquiring blood-borne viral infections, 
particularly among people who inject drugs [77–79]. 
Among people who use drugs, homelessness has been 
associated with public drug use, bacterial infections, nee-
dle sharing, overdose risk and hospitalization [80–82]. 
These results support the importance of individual and 
structural exposures in shaping health-related behaviors 
and healthcare utilization among young people who use 
drugs.
Strengths of this study include the prospective cohort 
design that performed repeated measures semi-annu-
ally. We also included a range of socio-demographic and 
drug use variables to provide a comprehensive analysis 
of risk factors for hospitalization. Through this method 
we were able to analyze multiple independent risk factors 
for hospitalization that were time-varying over the study 
period. Limitations of this study include collecting drug 
use and hospitalization measures through self-report, 
which introduced the potential for socially desirable 
reporting of stigmatized behaviors and recall error. It is 
also possible that the impact of these biases may have 
changed over the study period. Since the expansion of 
medical and recreational cannabis use policies has been 
linked to decreases in the stigmatization of cannabis use 
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behaviors, cannabis use may have been measured more 
accurately in recent follow-up visits compared to meas-
ures earlier in the study period [83]. If cannabis use did 
increase the risk of hospitalization and was underre-
ported in earlier follow-up visits, this may have attenu-
ated the association we observed between cannabis use 
and hospitalization. However, assessing these variables 
through self-report has been performed in previous 
studies and shown to provide valid and reliable meas-
urements [41, 84, 85]. It is also possible that measuring 
mental health disorders through self-report of previous 
diagnoses may have introduced recall error or bias, and 
undiagnosed mental health disorders were not captured 
in this assessment. People who use drugs and are liv-
ing with mental health disorders are less likely to access 
health and social services and frequently experience 
stigma and discrimination in healthcare settings [86]. 
Self-medication of psychiatric symptoms with drugs and 
alcohol is also common among people living with men-
tal health disorders and is associated with poorer health 
outcomes [87]. The potential harms associated with can-
nabis use among individuals with mental health condi-
tions may have been underestimated in the present study 
if undiagnosed mental health disorders prohibited these 
participants from accessing health services such as hospi-
tals. Including hospitalization events that are not attrib-
utable to cannabis use may have contributed to the lack 
of association observed between cannabis use and hos-
pitalization. Since data for the frequency of cannabis use 
per day were not available, we were not able to differ-
entiate people who used once per day from people who 
used multiple times per day. This may have prevented 
our measure of cannabis use frequency from isolating the 
most frequent cannabis users who may be at an increased 
risk to experience hospitalization. Assessing cannabis use 
and hospitalization at the same follow-up visit also cre-
ates uncertainty about the temporal relationship between 
cannabis use and hospitalization. It is possible that the 
direction of this association may be reversed if partici-
pants who were hospitalized were more likely to subse-
quently decrease their cannabis use. In addition, ARYS is 
not a random sample and given that ARYS is comprised 
of street-involved youth who use unregulated drugs in 
addition to cannabis, these results may not be generaliz-
able to young people who use cannabis and do not use 
other drugs. The use of other high-risk substances (e.g., 
cocaine, crystal methamphetamine) among our study 
sample is associated with an increased risk of hospitali-
zation and the additional  use of  cannabis may not sig-
nificantly increase the risk of hospitalization among 
people concurrently using other unregulated substances 
[41, 88]. Therefore, the association between cannabis use 
and hospitalization may be different among youth who 
use cannabis and do not also use high-risk unregulated 
substances. Although few participants died during the 
study (N = 14) and the distribution of these deaths did 
not vary by cannabis use (P = 0.781), it is possible that the 
association between cannabis use and health conditions 
requiring hospitalization may be different among older 
cannabis users who are more likely to experience canna-
bis-related harm associated with chronic use. Lastly, the 
potential for residual confounding to impact the associa-
tion between daily cannabis use and hospitalization is a 
concern due to the observational study design.
Conclusions
In the present study, we analyzed the association between 
daily cannabis use and hospitalization among a prospec-
tive cohort of street-involved youth. While daily cannabis 
use was not significantly associated with hospitalization 
in the whole sample, we observed sex-specific effects for 
the impact of cannabis use: daily cannabis use was associ-
ated with decreased rates of hospitalization among males 
and was not significantly associated with hospitalization 
among females. Given that a number of countries inter-
nationally are exploring novel approaches to the regula-
tion of recreational cannabis, future research is required 
to characterize the health and social consequences of 
cannabis use and determine how the regulatory frame-
works influence these outcomes and associated health-
care expenditures among the general population.
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